Shares

22 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

SELL
$1.02 - $3.23 $7,627 - $24,153
-7,478 Reduced 57.36%
5,559 $7,000
Q4 2023

Feb 15, 2024

SELL
$1.72 - $3.18 $29,761 - $55,023
-17,303 Reduced 57.03%
13,037 $35,000
Q3 2023

Nov 14, 2023

SELL
$2.13 - $5.55 $17,267 - $44,993
-8,107 Reduced 21.09%
30,340 $68,000
Q2 2023

Aug 14, 2023

BUY
$3.6 - $5.25 $56,606 - $82,551
15,724 Added 69.2%
38,447 $167,000
Q1 2023

May 15, 2023

BUY
$4.3 - $8.27 $24,798 - $47,693
5,767 Added 34.01%
22,723 $101,000
Q4 2022

Feb 14, 2023

BUY
$5.66 - $8.42 $95,970 - $142,769
16,956 New
16,956 $142,000
Q2 2022

Aug 22, 2022

SELL
$2.6 - $6.14 $39,574 - $93,456
-15,221 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$5.08 - $9.81 $76,514 - $147,758
-15,062 Reduced 49.74%
15,221 $87,000
Q4 2021

Feb 14, 2022

BUY
$8.55 - $111.89 $5,856 - $76,644
685 Added 2.31%
30,283 $296,000
Q3 2021

Nov 15, 2021

BUY
$76.53 - $110.43 $479,996 - $692,616
6,272 Added 26.89%
29,598 $3.13 Million
Q2 2021

Aug 12, 2021

BUY
$85.37 - $114.1 $445,375 - $595,259
5,217 Added 28.81%
23,326 $1.99 Million
Q1 2021

May 17, 2021

BUY
$109.73 - $153.66 $19,202 - $26,890
175 Added 0.98%
18,109 $2.08 Million
Q4 2020

Feb 12, 2021

BUY
$79.58 - $152.45 $175,314 - $335,847
2,203 Added 14.0%
17,934 $2.51 Million
Q3 2020

Nov 13, 2020

BUY
$66.43 - $90.99 $65,167 - $89,261
981 Added 6.65%
15,731 $1.28 Million
Q2 2020

Aug 14, 2020

BUY
$44.04 - $80.69 $39,107 - $71,652
888 Added 6.41%
14,750 $1.06 Million
Q1 2020

May 14, 2020

SELL
$44.49 - $93.39 $250,167 - $525,131
-5,623 Reduced 28.86%
13,862 $616,000
Q4 2019

Feb 13, 2020

BUY
$66.49 - $137.73 $837,175 - $1.73 Million
12,591 Added 182.64%
19,485 $1.86 Million
Q3 2019

Nov 13, 2019

BUY
$31.0 - $89.73 $106,826 - $309,209
3,446 Added 99.94%
6,894 $542,000
Q2 2019

Aug 14, 2019

BUY
$36.0 - $44.73 $20,052 - $24,914
557 Added 19.27%
3,448 $149,000
Q1 2019

May 15, 2019

BUY
$33.79 - $51.99 $48,353 - $74,397
1,431 Added 98.01%
2,891 $118,000
Q4 2018

Feb 15, 2019

BUY
$31.59 - $62.65 $6,602 - $13,093
209 Added 16.71%
1,460 $76,000
Q3 2018

Nov 20, 2018

BUY
$31.25 - $47.64 $39,093 - $59,597
1,251 New
1,251 $56,000

Others Institutions Holding ALLK

About Allakos Inc.


  • Ticker ALLK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 84,726,096
  • Market Cap $98.3M
  • Description
  • Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...
More about ALLK
Track This Portfolio

Track Legal & General Group PLC Portfolio

Follow Legal & General Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.